The Hive is a hub of innovation. It’s a group of leading-edge biotech and pharmaceutical start-ups that are specially chosen, because of their impressive work in early-stage drug discovery & development, to further power their efforts with complimentary access to Elsevier’s suite of R&D solutions.
Committed to promoting collaboration and inspiration across the Pharma & Life Sciences industry, The Hive is an opportunity for participating companies to accelerate their research and for others to learn from their experiences.
Enter your email address to follow The Hive and get the latest updates on participants and milestones
Questions, comments or inquiries about The Hive? Send us a message.
Meet the participants
Exemplifying the fresh, innovative, and agile world of R&D that is taking place outside the walls of Big Pharma, our four participants have the potential to change the industry’s landscape and improve the lives of patients. Discover the four companies selected to take part in The Hive and meet the people who make them tick.
Arctic Pharma AS
Aiming to be a leader in environmentally friendly cancer therapies that have few side effects, Arctic Pharma AS is a start-up company developing innovative anti-cancer drugs by exploiting the "sweet tooth" of cancer cells. The company targets key enzymes that are upregulated in cancer cell metabolism using inhibitors designed by them. This enables them to develop new pharmaceuticals with fewer side effects to combat cancer.
Read more about Arctic Pharma AS
Myelo Therapeutics is a Germany-based pharmaceuticals company that develops innovative treatments in areas of high unmet medical needs. The company’s lead compound, Myelo001 – the first new therapy option for chemotherapy-induced neutropenia (CIN) in over 20 years – is currently being investigated in a clinical trial.
Read more about Myelo Therapeutics
Reset Therapeutics is a discovery-stage biopharma company developing first-in-class approaches to treating diseases by restoring the body’s natural 24-hour, or circadian, rhythms. Reset’s pipeline includes new chemical entities designed to treat Cushing’s disease, type-2 diabetes and other metabolic disorders and narcolepsy and other disorders associated with excessive daytime sleepiness.
Read more about Reset Therapeutics
Rubius Therapeutics is using breakthrough science to develop a new class of drugs, Red-Cell Therapeutics™ (RCTs), with the potential to address many areas of human disease, including metabolic conditions, autoimmune disorders, cancer and infectious diseases. Using its rapid prototyping capability, the company has already generated more than 150 different RCT prototypes and is in the process of validating the most promising candidates for clinical entry.
Read more about Rubius Therapeutics
Elsevier R&D Solutions - Pharma & Life Sciences Solution Finder
From discovery to post-market, we offer solutions that can help you drive commercial success and manage risk. Answer a few questions to see which of our solutions can help you.
Already know which solutions are right for you?
Learn more about Elsevier's R&D solutions for drug discovery
and development utilized by The Hive participants
Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Learn more about Reaxys
Get started with Reaxys
Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Learn more about Embase
Get started with Embase
Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Learn more about Pathway Studio
Get started with Pathway Studio